Physician profile
Lynley Suzanne Holt
NPI 1043471329
$13,222.47
in general payments reported to CMS, 2019-2025
73 companies · $1,627 in 2025
The $1,627 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,525 · 2020: $1,494 · 2021: $2,509 · 2022: $1,815 · 2023: $2,109 · 2024: $2,143 · 2025: $1,627.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,879.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,878.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,631.46 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $1,262.09 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $1,228.67 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $1,137.07 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $786.05 | 2019-2025 | Jardiance |
| Pfizer INC. | $736.16 | 2019-2025 | |
| Preventric Diagnostics, INC. | $604.90 | 2021 | |
| Glaxosmithkline, LLC. | $519.21 | 2019-2025 | Trelegy Ellipta, Shingrix |
| Amgen INC. | $441.36 | 2019-2025 | Repatha, Otezla, Otezla |
| Merck Sharp & Dohme LLC | $383.02 | 2019-2025 | Verquvo, Belsomra, Gardasil 9 |
| Axsome Therapeutics, INC. | $316.87 | 2024-2025 | Auvelity |
| Bayer Healthcare Pharmaceuticals INC. | $284.94 | 2021-2025 | |
| Astellas Pharma US INC | $261.37 | 2019-2025 | Veozah, Myrbetriq |
| Amarin Pharma, INC. | $216.32 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $197.30 | 2019-2025 | Xifaxan, Trulance |
Show all 73 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $187.07 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $177.30 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $169.98 | 2019-2023 | |
| Eisai INC. | $163.12 | 2020-2025 | |
| Esperion Therapeutics, INC. | $149.17 | 2020-2025 | Nexletol |
| Janssen Pharmaceuticals, INC | $143.12 | 2019-2023 | Xarelto |
| Teva Pharmaceuticals USA, INC. | $126.48 | 2019-2023 | |
| Otsuka America Pharmaceutical, INC. | $120.41 | 2020-2025 | Rexulti |
| Cranial Technologies, INC | $113.44 | 2019-2025 | Doc Band |
| Sumitomo Pharma America, INC. | $109.71 | 2023-2024 | Gemtesa |
| Biohaven Pharmaceuticals, INC. | $100.93 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $93.66 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $87.25 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $71.47 | 2022 | |
| Daiichi Sankyo INC. | $66.37 | 2019-2023 | Injectafer |
| Genentech USA, INC. | $60.92 | 2019-2021 | |
| Avion Pharmaceuticals | $60.34 | 2020-2021 | |
| Baxter Healthcare | $59.54 | 2023 | Hillrom - Cardiac Ambulatory Monitor, Hillrom - Carnation Ambulatory Monitor |
| Ironwood Pharmaceuticals, INC | $57.54 | 2019-2023 | Linzess |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $55.84 | 2024-2025 | Caplyta |
| Xeris Pharmaceuticals, INC. | $55.57 | 2022-2023 | Gvoke Hypopen |
| Corium, LLC | $48.61 | 2023 | Adlarity, Azstarys |
| Philips North America LLC | $48.30 | 2024 | (Cm9) Amb Mon & Diag Und |
| Supernus Pharmaceuticals, INC. | $47.57 | 2021-2022 | |
| Corcept Therapeutics | $47.39 | 2024-2025 | Korlym |
| Mylan Specialty L.P. | $47.15 | 2023-2024 | Yupelri |
| Lundbeck LLC | $45.42 | 2023-2025 | Rexulti |
| Neotract INC. | $42.54 | 2019 | |
| Sunovion Pharmaceuticals INC. | $41.33 | 2022 | |
| Seqirus USA INC | $38.07 | 2021-2023 | Fluad Quadrivalent, Flucelvax Quadrivalent |
| Medtronic, INC. | $35.14 | 2022 | |
| Abbott Laboratories | $35.08 | 2024 | Freestyle Libre 3 |
| Vanda Pharmaceuticals INC. | $35.01 | 2025 | Fanapt |
| Idorsia Pharmaceuticals US INC | $34.00 | 2022-2023 | Quviviq |
| Neurocrine Biosciences, INC. | $30.18 | 2021-2025 | |
| Dexcom, INC. | $30.00 | 2022-2023 | Dexcom G6 Transmitter |
| Currax Pharmaceuticals LLC | $29.94 | 2020 | |
| Novavax INC | $26.20 | 2023 | Novavax Covid-19 Vaccine, Adjuvanted |
| Organogenesis INC. | $23.77 | 2024 | Puraply Am |
| Sanofi Pasteur INC. | $23.31 | 2024 | |
| Arbor Pharmaceuticals, INC. | $20.16 | 2020 | |
| Amneal Pharmaceuticals LLC | $19.48 | 2022 | |
| Exeltis, USA INC. | $19.37 | 2021 | |
| Collegium Pharmaceutical, INC. | $17.73 | 2025 | Jornay Pm |
| Shire North American Group INC | $17.53 | 2019 | |
| Phathom Pharmaceuticals, INC. | $16.72 | 2024 | Voquezna |
| Organon LLC | $16.21 | 2023 | Nexplanon |
| Aytu Biopharma, INC. | $15.68 | 2025 | |
| Nevro Corp. | $15.57 | 2019 | |
| Ironshore Pharmaceuticals INC. | $15.49 | 2023 | Jornay Pm |
| Upsher-Smith Laboratories LLC | $15.11 | 2021 | |
| Dermira, INC. | $14.51 | 2020 | |
| Inspire Medical Systems, INC. | $14.40 | 2025 | Inspire |
| Melinta Therapeutics, LLC | $13.51 | 2019 | |
| Impel Pharmaceuticals INC. | $12.16 | 2022 | |
| Tactile Systems Technology INC | $11.47 | 2021 | |
| Allergan, INC. | $11.42 | 2020 | |
| Advanced Respiratory, INC | $10.92 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lynley Holt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.